Moderna's efforts to develop a vaccine against the coronavirus has fuelled its stock rally. Reuters
Moderna's efforts to develop a vaccine against the coronavirus has fuelled its stock rally. Reuters
Moderna’s stock rally costs short sellers $1.5bn in 2020
The stock price could rise higher as the company starts a final-stage study of the vaccine this month
